[Form 4] METLIFE INC Insider Trading Activity
Laura J. Hay, a non‑management director of MetLife, Inc. (MET), reported a purchase of 534 shares of MetLife common stock on 10/01/2025 at a price of $81.93 per share. After the transaction, the reporting person beneficially owned 4,261 shares. The Form 4 notes these shares are part of the director retainer that the director elected to defer under the MetLife Deferred Compensation Plan for Non‑Management Directors. The filing was signed by an attorney‑in‑fact on 10/03/2025. The form contains no options or derivative transactions and no other changes to ownership were disclosed.
Laura J. Hay, una direttrice non esecutiva di MetLife, Inc. (MET), ha riportato l'acquisto di 534 azioni ordinarie MetLife il 10/01/2025 a un prezzo di $81,93 per azione. Dopo la transazione, la persona che segnala la posizione possedeva beneficiamente 4.261 azioni. Il Modulo 4 segnala che queste azioni fanno parte del compenso del consigliere che la direttrice ha deciso di differire secondo il MetLife Deferred Compensation Plan for Non‑Management Directors. La dichiarazione è stata firmata da un procuratore in data 10/03/2025. Il modulo non contiene opzioni o transazioni derivate e non sono state divulgate altre modifiche della proprietà.
Laura J. Hay, una directora no ejecutiva de MetLife, Inc. (MET), reportó la compra de 534 acciones comunes de MetLife el 01/10/2025 a un precio de $81,93 por acción. Después de la transacción, la persona que reporta poseía beneficiosamente 4.261 acciones. El Formulario 4 señala que estas acciones forman parte de la retribución del director que la directora decidió diferir bajo el MetLife Deferred Compensation Plan for Non‑Management Directors. La presentación fue firmada por un apoderado en 10/03/2025. El formulario no contiene opciones ni transacciones derivadas y no se revelaron otros cambios de propiedad.
Laura J. Hay는 MetLife, Inc. (MET)의 비경영층 이사로서 10/01/2025에 MetLife 보통주 534주를 매입했다고 보고했습니다. 주당 가격은 $81.93입니다. 거래 후 보고자 소유 주식 수는 4,261주로 증가했습니다. 형식 4에서는 이 주식 중 일부가 이사가 선택한 MetLife Deferred Compensation Plan for Non‑Management Directors 아래 이사 보수의 일부임을 명시하고 있습니다. 이 서류는 10/03/2025에 대리인 서명으로 제출되었습니다. 이 양식에는 옵션이나 파생 거래가 포함되어 있지 않으며 다른 소유권 변동도 공개되지 않았습니다.
Laura J. Hay, une administratrice non exécutive de MetLife, Inc. (MET), a signalé l'achat de 534 actions ordinaires MetLife le 10/01/2025 à un prix de $81,93 l'action. Après la transaction, la personne déclarant détenait avantageusement 4 261 actions. Le Formulaire 4 indique que ces actions font partie de la rémunération du directeur que la directrice a choisi de différer dans le MetLife Deferred Compensation Plan for Non‑Management Directors. Le dépôt a été signé par un procurateur le 10/03/2025. Le formulaire ne contient pas d'options ou de transactions dérivées et aucun autre changement de propriété n'a été divulgué.
Laura J. Hay, eine Nicht-Geschäftsführende Direktorin von MetLife, Inc. (MET), meldete den Kauf von 534 MetLife Stammaktien am 10/01/2025 zu einem Preis von $81,93 pro Aktie. Nach der Transaktion besaß die meldende Person vorteilhaft 4.261 Aktien. Das Formular 4 vermerkt, dass diese Aktien Teil der Direktorenvergütung sind, die die Direktorin gemäß dem MetLife Deferred Compensation Plan for Non‑Management Directors zu deferred. Die Einreichung wurde von einem Bevollmächtigten am 10/03/2025 unterschrieben. Das Formular enthält weder Optionen noch derivative Transaktionen, und es wurden keine weiteren Änderungen des Eigentums offengelegt.
لاورا ج. هاي، وهي عضو مجلس إدارة غير تنفيذي في MetLife, Inc. (MET)، ذكرت شراء 534 سهماً من أسهم MetLife العادية في 10/01/2025 بسعر $81.93 للسهم. بعد الصفقة، امتلكت الشخص المعلن بشكل فعّال 4,261 سهماً. يذكر النموذج 4 أن هذه الأسهم تشكل جزءاً من تعويضات المدير التي اختارت التأجيل بموجب MetLife Deferred Compensation Plan for Non‑Management Directors. تم توقيع الإيداع من قبل وكيلٌ قانوني في 10/03/2025. لا يحتوي النموذج على خيارات أو صفقات مشتقة ولم تُكشف أي تغييرات أخرى في الملكية.
Laura J. Hay，MetLife, Inc.（MET）的非管理层董事报告在2025/01/10以每股$81.93的价格购买了534股MetLife普通股。交易后，报告人实际持有的股数为4,261股。这些股票属于董事报酬的一部分，董事选择根据MetLife Deferred Compensation Plan for Non‑Management Directors进行递延。该申报表由代理律师签署，日期为2025/03/10。该表格不包含期权或衍生交易，也未披露其他所有权变动。
- Director purchased 534 shares, increasing alignment with shareholders
- Shares deferred under company plan, indicating use of standard compensation program
- Beneficial ownership of 4,261 shares reported, providing transparency
- None.
Insights
Director acquired 534 MetLife shares at $81.93 on 10/01/2025.
The reported purchase increases the director's direct holding to 4,261 shares, reflecting compensation payment converted to stock and deferred under the company's director deferred compensation plan.
This transaction is disclosed as compensation‑related rather than a discretionary market purchase, which is typical for non‑management director retainer arrangements and signals routine ownership accumulation consistent with board compensation policy.
Transaction arises from director retainer deferral; no derivatives or unusual dispositions.
The Form 4 explicitly states the shares are part of the non‑management director retainer and were deferred under the MetLife Deferred Compensation Plan for Non‑Management Directors, indicating this is a standard compensation settlement, not ad hoc trading.
Such filings confirm compliance with Section 16 reporting and provide transparency on director ownership levels; the filing contains no additional governance events.
Laura J. Hay, una direttrice non esecutiva di MetLife, Inc. (MET), ha riportato l'acquisto di 534 azioni ordinarie MetLife il 10/01/2025 a un prezzo di $81,93 per azione. Dopo la transazione, la persona che segnala la posizione possedeva beneficiamente 4.261 azioni. Il Modulo 4 segnala che queste azioni fanno parte del compenso del consigliere che la direttrice ha deciso di differire secondo il MetLife Deferred Compensation Plan for Non‑Management Directors. La dichiarazione è stata firmata da un procuratore in data 10/03/2025. Il modulo non contiene opzioni o transazioni derivate e non sono state divulgate altre modifiche della proprietà.
Laura J. Hay, una directora no ejecutiva de MetLife, Inc. (MET), reportó la compra de 534 acciones comunes de MetLife el 01/10/2025 a un precio de $81,93 por acción. Después de la transacción, la persona que reporta poseía beneficiosamente 4.261 acciones. El Formulario 4 señala que estas acciones forman parte de la retribución del director que la directora decidió diferir bajo el MetLife Deferred Compensation Plan for Non‑Management Directors. La presentación fue firmada por un apoderado en 10/03/2025. El formulario no contiene opciones ni transacciones derivadas y no se revelaron otros cambios de propiedad.
Laura J. Hay는 MetLife, Inc. (MET)의 비경영층 이사로서 10/01/2025에 MetLife 보통주 534주를 매입했다고 보고했습니다. 주당 가격은 $81.93입니다. 거래 후 보고자 소유 주식 수는 4,261주로 증가했습니다. 형식 4에서는 이 주식 중 일부가 이사가 선택한 MetLife Deferred Compensation Plan for Non‑Management Directors 아래 이사 보수의 일부임을 명시하고 있습니다. 이 서류는 10/03/2025에 대리인 서명으로 제출되었습니다. 이 양식에는 옵션이나 파생 거래가 포함되어 있지 않으며 다른 소유권 변동도 공개되지 않았습니다.
Laura J. Hay, une administratrice non exécutive de MetLife, Inc. (MET), a signalé l'achat de 534 actions ordinaires MetLife le 10/01/2025 à un prix de $81,93 l'action. Après la transaction, la personne déclarant détenait avantageusement 4 261 actions. Le Formulaire 4 indique que ces actions font partie de la rémunération du directeur que la directrice a choisi de différer dans le MetLife Deferred Compensation Plan for Non‑Management Directors. Le dépôt a été signé par un procurateur le 10/03/2025. Le formulaire ne contient pas d'options ou de transactions dérivées et aucun autre changement de propriété n'a été divulgué.
Laura J. Hay, eine Nicht-Geschäftsführende Direktorin von MetLife, Inc. (MET), meldete den Kauf von 534 MetLife Stammaktien am 10/01/2025 zu einem Preis von $81,93 pro Aktie. Nach der Transaktion besaß die meldende Person vorteilhaft 4.261 Aktien. Das Formular 4 vermerkt, dass diese Aktien Teil der Direktorenvergütung sind, die die Direktorin gemäß dem MetLife Deferred Compensation Plan for Non‑Management Directors zu deferred. Die Einreichung wurde von einem Bevollmächtigten am 10/03/2025 unterschrieben. Das Formular enthält weder Optionen noch derivative Transaktionen, und es wurden keine weiteren Änderungen des Eigentums offengelegt.
FAQ
What transaction did MetLife director Laura J. Hay report (MET)?
How many MetLife shares does the reporting person own after the reported transaction?
Was the purchase part of a compensation or discretionary trade?
Did the Form 4 disclose any derivative or option transactions?
When was the Form 4 signed and filed?
